A5063374045- Lipoproteins and Cardiovascular Health
- Adipokines, Inflammation, and Metabolic Diseases
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Disease and Adiposity
- Atherosclerosis and Cardiovascular Diseases
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pharmaceutical Practices and Patient Outcomes
- Cardiac Health and Mental Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Liver Disease Diagnosis and Treatment
- Inflammasome and immune disorders
- Pharmaceutical Economics and Policy
- Anesthesia and Sedative Agents
- Medication Adherence and Compliance
University of Milan
2021-2025
MultiMedica
2024
Abstract Chronic low-degree inflammation is a hallmark of atherosclerotic cardiovascular (CV) disease. To assess the effect lipid-lowering therapies on C-reactive protein (CRP), biomarker inflammation, we conducted meta-analysis according to PRISMA guidelines. Databases were searched from inception July 2023. Inclusion criteria were: (i) randomized controlled trials (RCTs) in human, Phase II, III, or IV; (ii) English language; (iii) comparing drugs vs. placebo; (iv) reporting effects CRP...
Polypharmacy, defined as the concurrent use of multiple medications, increases risk various adverse outcomes. However, variability in definitions across literature contributes to substantial heterogeneity. Building on published literature, this study aimed identify a set operational polypharmacy applicable administrative databases and assess their association with all-cause hospitalization. Data from pharmacy refill hospitalization Local Health Unit (LHU) Bergamo, Lombardy, were analyzed....
Dear Editor, Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Although several therapeutic options are available to reduce LDL-cholesterol (LDL-C), many patients continue experience major (CV) events. In ASCVD, inflammation plays a critical role, contributing significantly residual CV risk [1]. Several anti-inflammatory therapies have been evaluated risk, recently, U.S. Food Drug Administration approved use low-dose colchicine...
Introduction: Current European guidelines on cardiovascular prevention recommend lipid-lowering therapies for patients who have experienced an atherosclerotic disease (ASCVD) event. Objectives: This study aims to provide updated data the prescription of in discharged after ASCVD event and investigate characteristics associated with a higher likelihood receiving such therapy following Methods: Using administrative from Lombardy region, individuals both sexes aged ≥40 years hospitalized...
Background: Lipoprotein(a) [Lp(a)] is a relatively new but underutilized biomarker in the context of atherosclerotic cardiovascular disease (ASCVD). Objectives: To explore clinical implementation Lp(a) measurement and current practices hospital specialised settings Italy. Methods: An anonymous online questionnaire was distributed to Italian physicians examine habits clinicians regarding measurement. The survey covered three topics: 1) information on setting physicians, 2) questions for who...
Aim: Epidemiological studies, Mendelian randomized and genome-wide association studies confirmed that elevated lipoprotein(a) [Lp(a)] concentration is an independent risk factor for cardiovascular diseases. However, no approved therapy patients with Lp(a) levels available. Our aim to investigate what extent PCSK9 inhibitors (PCSK9i), statins, ezetimibe affect level. Methods: This meta-analysis was conducted according the PRISMA guidelines. Databases were searched from inception February...
The XVII National Congress of the Società Italiana di Terapia Clinica e Sperimentale (SITeCS) was held in Milan on October 12-14, 2023. As is now customary, organised collaboration with Italian Society for Study Atherosclerosis (SISA) Lombardy Region. included a discussion most recent evidence or topical issues clinical and pharmacological research as well presentations scientific work by young researchers. A short report main debated during 2022 lectures offered this issue, benefit European...